By Andrea Park
The manufacturing facility's closure and subsequent layoffs will take effect Jan. 30.
read more
By Heather Landi
Healthcare merger and acquisition activity hit a new stride in 2021, fueled by investor interest in digital health and virtual care as well as the SPAC craze that's pumping a lot of cash into the market.
read more
By Kevin Dunleavy
In a move to diversify its business, Australian biopharma CSL has agreed to acquire Vifor Pharma for $11.7 billion. The deal would give CSL—heavily dependent on vaccines and blood plasma products—Vifor’s attractive kidney disease and iron deficiency franchises.
read more
By Annalee Armstrong
Galera’s shares were pummeled in the wake of news that its radiotherapy complication drug flunked a phase 3 study, but now the biotech says the study results were in error, and the treatment did, in fact, work.
read more
By Paige Minemyer
As part of its ongoing examination of its portfolio, Centene Corporation is "evaluating strategic alternatives" for its businesses abroad.
read more
By Annalee Armstrong
Pfizer said it expects its antiviral pill Paxlovid to provide protection against the omicron variant of the coronavirus, amid worldwide concern that existing medications and vaccines would not work against the newly mutated version.
read more
By Conor Hale
Philips is looking to bolster its vascular franchise by absorbing Vesper Medical, maker of stents designed to open up blocked or narrowed veins in the legs.
read more
By Ben Adams
Sleepless nights are nothing new to most people, but chronic insomnia takes this to another level. Idorsia, awaiting an FDA approval for its sleep drug, has set up an alliance to research the condition.
read more
By Fraiser Kansteiner
Fujifilm Diosynth Biotechnologies is splashing out $300 million to build a new production facility at its single-use manufacturing campus in College Station, Texas, the company said Tuesday. Alongside a major biologics capacity upgrade, the expansion is set to add 150 new jobs by 2024—the same year that the new facility is expected to come online.
read more
By Annalee Armstrong
Generation Bio’s shares were briefly halted Tuesday morning on the release of mouse data that complicated its search for a viable target for hemophilia A to take into the clinic.
read more
By Robert King
A newly released version of the Build Back Better Act nixes cuts to disproportionate share hospital payments to facilities in states that did not expand Medicaid.
read more
By Andrea Park
Nearly two years after BrainsGate submitted its implantable neurostimulation device for FDA premarket approval, an advisory panel for the agency struck a major blow to the Israeli company’s plans.
read more
By Rebecca Torrence
HealthCare.com, which connects consumers with health plans, is now a unicorn after closing a $180 million round that boosted its valuation to more than $1 billion.
read more
By Kyle LaHucik
Sanofi's hemophilia drug, put on pause last year, could be closer to the FDA's doorstep on new late-stage data that shows the treatment significantly reduced bleeds. But the adverse events that raised red flags are still persisting in one study.
read more
